Finished Product

1206-33

Vet Systems - Orthobiologics

Product

The ACP Max device is a buffy-coat-based system used to facilitate the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a sample of the patient's own blood.
 
Interest in the use of autologous blood products in various orthopedic procedures has been on the rise. PRP can be used at the point of care for treatment of osteoarthritis or mixed with autograft or allograft bone prior to application.

ACP Max™ PRP System

Child (D)

The Arthrex ACP double-syringe system is used to facilitate the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient’s point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements. There has been increased interest in autologous blood products for use in a number of orthopedic therapies.

Arthrex ACP® Double-Syringe System

Vet Systems - Small Animal

Defects in articular cartilage can induce osteoarthritis by causing molecular changes in the synovial fluid. Research in molecular biology discovered the major inducer of osteoarthritis was the general inflammatory cytokine interleukin-1 (IL-1) which plays a key role in accelerating tissue destruction and the repair mechanisms.
 
In a healthy joint, IL-1 and interleukin-1 receptor antagonist (IL-1Ra) are in balanced concentrations. In cases of osteoarthritis, there is not sufficient IL-1Ra produced to block the destructive effects of the increased IL-1. The result is inflammation, joint pain, and eventually cartilage destruction. In the IRAP II system, monocytes (a type of white blood cell) bind to the glass beads. The cells are then stimulated to produce regenerative and anti-inflammatory proteins without the addition of drugs. This process takes place over an incubation period of 24 hours.
 
IRAP II is used to treat mild to moderate osteoarthritis in animals.

IRAP II™ System

Defects in articular cartilage can induce osteoarthritis by causing molecular changes in the synovial fluid. Research in molecular biology discovered the major inducer of osteoarthritis was the general inflammatory cytokine interleukin-1 (IL-1), which plays a key role in accelerating tissue destruction and the repair mechanisms.
 
In a healthy joint, IL-1 and interleukin-1 receptor antagonist (IL-1Ra) are in balanced concentrations. In osteoarthritis, the IL-1Ra produced is insufficient to block the destructive effects of the increased IL-1. The result is inflammation, joint pain, and eventually cartilage destruction. Using the Arthrex IRAP™ ProEAS system, monocytes (a type of white blood cell) from the animal’s harvested blood bind to the glass beads in the device. The cells are stimulated over 24 hours of incubation to produce regenerative and anti-inflammatory proteins without the addition of drugs. The autologous serum produced using the Arthrex IRAP ProEAS device may be used to treat mild to moderate osteoarthritis in animals.

Hettich Rotofix 32A, Centrifuge

1206-33

Related Pages

Orthobiologics

ACP Max™ PRP System

Product

Orthobiologics

Arthrex ACP^® Double-Syringe System

Product

Small Animal

IRAP II™ System

Product

Orthobiologics

IRAP ProEAS™ System

Product